Mustang Bio announces phase 1 clinical trial evaluating MB-105 for prostate cancer
Mustang Bio announced that City of Hope has opened and is beginning to treat its first patients in a Phase 1 clinical trial of MB-105, a prostate stem cell antigen chimeric antigen receptor (CAR) T technology, for the treatment of prostate cancer. September 23, 2019